Eli Lilly and Company (LLY)
| Market Cap | 674.60B |
| Revenue (ttm) | 49.00B |
| Net Income (ttm) | 11.11B |
| Shares Out | 897.74M |
| EPS (ttm) | 12.29 |
| PE Ratio | 61.14 |
| Forward PE | 30.17 |
| Dividend | $6.00 (0.80%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 6,162,033 |
| Open | 765.00 |
| Previous Close | 776.72 |
| Day's Range | 739.08 - 769.98 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 1,005.05 (+33.75%) |
| Earnings Date | May 1, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,005.05, which is an increase of 33.75% from the latest price.
News
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Top Stock Movers Now: AB InBev, Molson Coors, Eli Lilly, and More
U.S. equities advanced at midday as President Donald Trump announced a new trade deal with the United Kingdom. The Dow Jones Industrial Average, S&P 500, and Nasdaq all rose.
Lilly announces transitions in executive leadership
INDIANAPOLIS , May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-t...
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly's blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply, ...
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Pharma sector still investable, faces added headwinds, says BMO's Siegerman
Evan Siegerman, BMO Capital Markets, joins 'Fast Money' to talk new headwinds facing the pharma sector.
Trump Sets Pharma Tariffs Deadline. The Fallout for Eli Lilly, Pfizer, Other Drugmakers.
The president signed an executive order to promote domestic pharma production Monday, and said that news on drug tariffs will come within two weeks.
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
Lilly declares second-quarter 2025 dividend
INDIANAPOLIS , May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common st...
Top 50 High-Quality Dividend Stocks For May 2025
I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. Despite a market sell-off, my investable univer...
Eli Lilly's Meltdown Triggers Near Doubling Upside Potential - Reiterate Buy
LLY's valuation remains highly attractive post-market overreaction, with the FY2025 bottom-line impact merely attributed to one-time acquired IPR&D expenses from ongoing M&A activities. Despite the ta...
Eli Lilly: Don't Overthink This Buying Opportunity
Eli Lilly faced a 12% drop due to CVS formulary changes favoring Novo Nordisk, but I explain why this seems overstated. Lilly has gained control as the US market leader for GLP-1 drugs, and is still m...
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly and Co LLY on Thursday reported first-quarter earnings and lowered its 2025 guidance.
Calls of the Day: AutoZone, Roblox, Eli Lilly, Johnson & Johnson and Quanta Services
Oppenheimer upgrades AutoZone — NewEdge Wealth CEO Rob Sechan owns it and breaks it down, while the Investment Committee drops their latest picks.
Eli Lilly's Stock Selloff Is Overdone, Analysts Say. Here's Why.
Analysts were rushing to reiterate their conviction in the stock following Thursday's blow to Zepbound and Lilly shares.
Lilly to participate in Bank of America Securities 2025 Healthcare Conference
INDIANAPOLIS , May 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025. Lucas Montarce, Lilly executive...
The GLP-1 Saga Continues, And How
Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are no longer considered to officially be in shortage.
Eli Lilly's worst day in nearly 17 years: Strategist Jared Holz on Q1 results
Jared Holz, Mizuho Securities health care strategist, joins 'Fast Money' to discuss Eli Lilly's biggest day drop since 2008 and the obesity drug competition.
Breaking down 3 takeaways from healthcare earnings
Yahoo Finance Senior Health Reporter Anjalee Khemlani joins the Wealth team in breaking down the biggest themes she is seeing in the healthcare space from this earnings season, ranging from CVS Health...
Eli Lilly and Company (LLY) Q1 2025 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations Dave Ricks - Chair and CEO Luca...
Kohl's Jumps After Firing CEO, Eli Lilly Tumbles, Microsoft Soars | Stock Movers Podcast
Get more equity coverage like this on the Stock Movers podcast from Bloomberg, featuring five-minute episodes on the winners and losers in the stock market. Subscribe here: https://link.podtrac.com/h0...
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly's obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to CVS's ex...
Eli Lilly earnings topped estimates, so why the stock is sinking?
Eli Lilly (LLY) shares slid at the open despite topping first quarter estimates, with investors reacting to the company lowering its full-year profit outlook. Investors are also reacting to a new deal...
Eli Lilly CEO David Ricks on pricing of the new weight loss pill if approved
Eli Lilly chairman and CEO David Ricks discusses the status of the company's weight loss drug pill.
QCOM Earnings Sell-Off, CVS Turnaround Continues, LLY Disappoints
While Microsoft (MSFT) and Meta Platforms (META) shined in the Big Tech space, Diane King Hall turns to a mixed earnings picture elsewhere on Wall Street. CVS Health (CVS) posted an earnings beat, rai...